Sign Up
Stories
Adcetris Boosts Lymphoma Patients' Survival
Share
Advancements in Cancer Treatment and Mar...
BioRestorative Therapies Raises $81 Mill...
Biopharma Companies Announce Public Offe...
Acquisition Progress Amid Safety Concern
Afya Limited Expands Medical Seats in Br...
Agile Leadership Training for Pharma Pro...
Overview
API
Pfizer's Adcetris demonstrates improved overall survival for diffuse large B-cell lymphoma patients. The drug, in combination therapy, enhances partial cancer reductions and survival rates, approved by the FDA and EU.
Ask a question
How might the success of Adcetris impact future developments in cancer treatment and pharmaceutical research?
In what ways could the shift towards oncology impact Pfizer's revenue streams and competitive position in the pharmaceutical market?
What challenges or opportunities could Pfizer face in scaling up production and distribution of Adcetris globally?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage